Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.50 |
| ▸ | EGFR | P00533 | 6/20 | 0.50 |
| ▸ | GAK | O14976 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | FLT1 | P17948 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | ILK | Q13418 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14540941 | 0.84 | KDM1A (0.41) | KDM1AEGFRGAKFGFR1FLT1 | |
| SCHEMBL14540937 | 0.84 | SRC (0.44) | KDM1AEGFRGAKFGFR1FLT1 | |
| SCHEMBL5052304 | 0.83 | FGFR1 (0.54) | KDM1AEGFRGAKFGFR1FLT1 | |
| SCHEMBL29736268 | 0.83 | EHMT2 (0.60) | KDM1AEGFRGAKFGFR1FLT1 | |
| SCHEMBL30465547 | 0.83 | FLT1 (0.54) | KDM1AEGFRGAKFGFR1FLT1 | |
| SCHEMBL2748495 | 0.83 | FLT1 (0.54) | KDM1AEGFRGAKFGFR1FLT1 | |
| SCHEMBL16070093 | 0.82 | EHMT2 (0.50) | KDR | |
| SCHEMBL1496287 | 0.81 | PDGFRB (0.57) | EGFRGAK | |
| SCHEMBL3688152 | 0.79 | MAOA (0.52) | EGFRFGFR1FLT1KDRILK | |
| SCHEMBL22441436 | 0.79 | KDR (0.60) | EGFRGAKFGFR1FLT1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219929-A1 | INHIBITORS OF MET KINASE | CELYN THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219929-A1 | INHIBITORS OF MET KINASE | MET, RET, MERTK | KDM1A 1163/4885EGFR 8/4885GAK 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.